Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Logistics and feasibility
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Type 2 myocardial infarction (MI) is defined as myocardial necrosis that results from an imbalance of myocardial oxygen supply and demand. Although type 2 MI is highly prevalent in patients with critical illness and strongly associated with mortality, the pathophysiology remains poorly understood. Inflammation is central to the development of atherosclerosis, plaque rupture, and other subtypes of MI, but the role of inflammation in type 2 MI and myocardial necrosis has not been defined. The investigators aim to to delineate the mechanistic role of inflammation in myocardial necrosis and type 2 MI complicating critical medical illness.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Critical illness and type 2 MI | Critically ill adults with abnormal serum troponin I during hospitalization for critical illness. | ||
| Critical illness without type 2 MI | Critically ill adults without an elevation in troponin I complicating critical illness. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Leukocyte-platelet aggregates | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Leukocyte-platelet aggregates | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 10 |
| Monocyte-platelet aggregates | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| EndoPAT score | Day 1 | |
| EndoPAT score | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 10 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults admitted to the Medical Intensive or Coronary Care Units (MICU or CCU)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Binita Shah, MD, MS | NYU School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bellevue Hospital Center | New York | New York | 10016 | United States |
Not provided
| ID | Term |
|---|---|
| D009203 | Myocardial Infarction |
| D007249 | Inflammation |
| D016638 | Critical Illness |
| D009336 | Necrosis |
| D018805 | Sepsis |
| D012131 | Respiratory Insufficiency |
| D017202 | Myocardial Ischemia |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D014652 | Vascular Diseases |
| ID | Term |
|---|---|
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Venous blood samples
| Monocyte-platelet aggregates | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 10 |
| Neutrophil-platelet aggregates | Day 1 |
| Neutrophil-platelet aggregates | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 10 |
| surface L-selectin |
| Day 1 |
| surface L-selectin | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 10 |
| soluble L-selectin | Day 1 |
| soluble L-selectin | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 10 |
| surface CD11b | Day 1 |
| surface CD11b | Participants will be followed for the duration of hospital stay, an expected average of 10 days. | Day 1 |
| D020969 |
| Disease Attributes |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |